Evotec and IR Pharma Establish Drug Discovery Alliance in the Field of Respiratory


Hamburg, Germany - 16 February 2012: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) and IR Pharma today announced that they have entered into an exclusive strategic alliance to provide integrated drug discovery solutions to Pharmaceutical and Biotech companies in the field of Respiratory Diseases.

This alliance expands Evotec's already powerful drug discovery platform, into the area of respiratory diseases through IR Pharma's world leading expertise in in vitro and in vivo Respiratory pharmacology. As part of this exclusive collaboration, Evotec is now positioned to offer seamless, fully integrated respiratory and inflammation focused drug discovery programmes to its partners, from target to nomination of pre-clinical development candidates.

Dr Mario Polywka, Chief Operating Officer at Evotec AG, commented: "We are looking forward to partner with IR Pharma and are excited about the potential of this alliance. IR Pharma has outstanding expertise in the respiratory disease area including disease relevant in vivo models and coupled with our world leading discovery engine and commercial reach, we are sure we can bring outstanding value to existing and future partners and collaborators in these demanding disease areas. This co-operation is a significant addition to our strategy to offer the most comprehensive drug discovery solutions to our partners."

Prof Maria Belvisi, Director at IR Pharma Ltd, added: "We are delighted to join forces with Evotec and firmly believe that together, we will provide efficient and innovative drug discovery solutions to our partners. We have a range of highly validated models, focusing on Asthma, Cough and Chronic Obstructive Pulmonary Disease (COPD), which ideally complement Evotec's platform, thus enabling a fully integrated approach to drug discovery in this challenging area."

No financial details were disclosed.